Narazaciclib is under clinical development by Onconova Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Narazaciclib’s likelihood of approval (LoA) and phase transition for Colorectal Cancer took place on 26 Oct 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Narazaciclib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Narazaciclib overview

ON-123300 is under development for the treatment of solid tumors and hematological tumors including glioblastoma multiforme, colorectal cancer, multiple myeloma, mantle cell lymphoma, hepatocellular carcinoma, recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC) and HER-2 negative metastatic breast cancer including triple-negative breast cancer. It is a small molecule administered orally. It acts by targeting cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase 6 (CDK6)  enzyme and ARK5.

Onconova Therapeutics overview

Onconova Therapeutics (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib and ON123300. It develops drug candidates that target cancer and protect healthy cells based on its proprietary chemistry platform and cell-based differential screening. Onconova’s rigosertib is targeted at meeting the medical needs of patients with myelodysplastic syndromes. The company’s recilisib is used to treat the effects of acute radiation syndromes such as cytopenia. It partners with biopharmaceutical companies and medical organizations in the US. Onconova is headquartered in Newtown, Pennsylvania, the US.

Quick View Narazaciclib LOA Data

Report Segments
  • Innovator
Drug Name
  • Narazaciclib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.